The Association of the British Pharmaceutical Industry (ABPI) has welcomed the Welsh Government’s ‘go-live’ of a £80 million New Treatment Fund aimed at speeding up Welsh NHS patient access to the very latest medicines.
The new funding mechanism, advocated for by the ABPI in the build-up to the 2016 National Assembly for Wales elections as a way of delivering “equitable and consistent patient access to the latest medicines, no matter the disease area”, will provide additional support of £16 million annually to Welsh health boards until 2021.
Under the new system, confirmed today by Health Secretary Vaughan Gething, AM, all health boards in Wales will be required to make a National Institute for Health and Care Excellence (NICE) or All Wales Medicines Strategy Group (AWMSG) recommended medicine available no later than two months from the date guidance is published.
Dr Rick Greville, ABPI Director with responsibility for Wales commented:
“Today’s announcement is great news for NHS patients in Wales and is the type of progressive policy which can make a real impact on patients’ lives. It demonstrates the ambition of the Welsh Government to provide a quality health system across all disease areas, based on evidence and prudent principles.
To the frustration of patients and clinicians, we know that health boards have faced financial challenges in planning for the introduction of innovative treatments. The additional £80 million offered by this New Treatment Fund over five years should overcome these concerns, enabling health boards to be early adopters of all medicines shown to be cost and clinically effective.
From today, the people of Wales should look forward to the prospect of benefitting from the right medicines, for all patients, at the earliest time.”
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.